A Monoclonal Human Alveolar Epithelial Cell Line (“Arlo”) with Pronounced Barrier Function for Studying Drug Permeability and Viral Infections
Abstract In the development of orally inhaled drug products preclinical animal models regularly fail to predict pharmacological as well as toxicological responses in humans. Models based on human cells and tissues are potential alternatives to animal experimentation allowing for the isolation of essential processes of human biology and making them accessible in vitro. Here, the generation of a novel monoclonal cell line “Arlo,” derived from the polyclonal human alveolar epithelium lentivirus immortalized cell line hAELVi via single‐cell printing, and its characterization as a model for the human alveolar epithelium as well as a building block for future complex in vitro models is described. “Arlo” is systematically compared in vitro to primary human alveolar epithelial cells (hAEpCs) as well as to the polyclonal hAELVi cell line. “Arlo” cells show enhanced barrier properties with high transepithelial electrical resistance (TEER) of ≈3000 Ω cm2 and a potential difference (PD) of ≈30 mV under air–liquid interface (ALI) conditions, that can be modulated. The cells grow in a polarized monolayer and express genes relevant to barrier integrity as well as homeostasis as is observed in hAEpCs. Successful productive infection with severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) in a proof‐of‐principle study offers an additional, attractive application of “Arlo” beyond biopharmaceutical experimentation..
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:10 |
|---|---|
| Enthalten in: |
Advanced Science - 10(2023), 8 |
| Beteiligte Personen: |
Carius, Patrick [VerfasserIn] |
|---|
| Anmerkungen: |
© 2023 Wiley‐VCH GmbH |
|---|
| Umfang: |
23 |
|---|
| doi: |
10.1002/advs.202207301 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
WLY014881098 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | WLY014881098 | ||
| 003 | DE-627 | ||
| 005 | 20231111121517.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231111s2023 xx |||||o 00| ||und c | ||
| 024 | 7 | |a 10.1002/advs.202207301 |2 doi | |
| 028 | 5 | 2 | |a 2023-11-11_ADVS_2023_10_8.zip.xml |
| 035 | |a (DE-627)WLY014881098 | ||
| 035 | |a (WILEY)ADVS5123 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rda | ||
| 100 | 1 | |a Carius, Patrick |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a A Monoclonal Human Alveolar Epithelial Cell Line (“Arlo”) with Pronounced Barrier Function for Studying Drug Permeability and Viral Infections |
| 264 | 1 | |c 2023 | |
| 300 | |a 23 | ||
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a © 2023 Wiley‐VCH GmbH | ||
| 520 | |a Abstract In the development of orally inhaled drug products preclinical animal models regularly fail to predict pharmacological as well as toxicological responses in humans. Models based on human cells and tissues are potential alternatives to animal experimentation allowing for the isolation of essential processes of human biology and making them accessible in vitro. Here, the generation of a novel monoclonal cell line “Arlo,” derived from the polyclonal human alveolar epithelium lentivirus immortalized cell line hAELVi via single‐cell printing, and its characterization as a model for the human alveolar epithelium as well as a building block for future complex in vitro models is described. “Arlo” is systematically compared in vitro to primary human alveolar epithelial cells (hAEpCs) as well as to the polyclonal hAELVi cell line. “Arlo” cells show enhanced barrier properties with high transepithelial electrical resistance (TEER) of ≈3000 Ω cm2 and a potential difference (PD) of ≈30 mV under air–liquid interface (ALI) conditions, that can be modulated. The cells grow in a polarized monolayer and express genes relevant to barrier integrity as well as homeostasis as is observed in hAEpCs. Successful productive infection with severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) in a proof‐of‐principle study offers an additional, attractive application of “Arlo” beyond biopharmaceutical experimentation. | ||
| 700 | 1 | |a Jungmann, Annemarie |4 aut | |
| 700 | 1 | |a Bechtel, Marco |4 aut | |
| 700 | 1 | |a Grißmer, Alexander |4 aut | |
| 700 | 1 | |a Boese, Annette |4 aut | |
| 700 | 1 | |a Gasparoni, Gilles |4 aut | |
| 700 | 1 | |a Salhab, Abdulrahman |4 aut | |
| 700 | 1 | |a Seipelt, Ralf |4 aut | |
| 700 | 1 | |a Urbschat, Klaus |4 aut | |
| 700 | 1 | |a Richter, Clémentine |4 aut | |
| 700 | 1 | |a Meier, Carola |4 aut | |
| 700 | 1 | |a Bojkova, Denisa |4 aut | |
| 700 | 1 | |a Cinatl, Jindrich |4 aut | |
| 700 | 1 | |a Walter, Jörn |4 aut | |
| 700 | 1 | |a Schneider‐Daum, Nicole |4 aut | |
| 700 | 1 | |a Lehr, Claus‐Michael |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Advanced Science |g 10(2023), 8 |w (DE-627)WLY000452548 |x 21983844 |7 nnns |
| 773 | 1 | 8 | |g volume:10 |g year:2023 |g number:8 |g extent:23 |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_WLY | ||
| 951 | |a AR | ||
| 952 | |d 10 |j 2023 |e 8 |g 23 | ||